Carpal Tunnel Syndrome: As Seen from the Perspective of the Patient

Autor: Christian L. Blough, MD, Stuart H. Kuschner, MD, Haben Berihun, BS, Cassie C. Tseng, OT, David A. Kulber, MD

Publikováno v: Plastic and Reconstructive Surgery, Global Open, Vol 11, Iss 7, p e5146 (2023)

Background:. Carpal tunnel syndrome (CTS) is the most common nerve compression syndrome in the upper extremity and is one of the most common problems treated by hand surgeons. Despite its ubiquity—or perhaps because of it—there is a lack of unani

Externí odkaz: https://doaj.org/article/f1855d8da875495abd876041dd72bd3d

Hyperpolarized C-13 MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring

Autor: Ronen, Sabrina, Chaumeil, MM, Radoul, M, Najac, C, Eriksson, P, Viswanath, P, Blough, MD, Chesnelong, C, Luchman, HA, Cairncross, JG, Ronen, SM

Publikováno v: Ronen, Sabrina; Chaumeil, MM; Radoul, M; Najac, C; Eriksson, P; Viswanath, P; et al.(2016). Hyperpolarized C-13 MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/0pj5z00w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::8b2a6de0e123f066f861ca7f7f63fc2c
http://www.escholarship.org/uc/item/0pj5z00w

Single-cell landscapes of primary glioblastomas and matched explants and cell lines show variable retention of inter- and intratumor heterogeneity.

Autor: LeBlanc VG; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, V5Z 4S6 BC, Canada., Trinh DL; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, V5Z 4S6 BC, Canada., Aslanpour S; Department of Clinical Neurosciences, University of Calgary, Calgary, T2N 2T9 AB, Canada; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, T2N 4Z6 AB, Canada., Hughes M; Department of Clinical Neurosciences, University of Calgary, Calgary, T2N 2T9 AB, Canada; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, T2N 4Z6 AB, Canada., Livingstone D; Department of Clinical Neurosciences, University of Calgary, Calgary, T2N 2T9 AB, Canada; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, T2N 4Z6 AB, Canada., Jin D; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, V5Z 4S6 BC, Canada., Ahn BY; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, T2N 4Z6 AB, Canada., Blough MD; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, T2N 4Z6 AB, Canada., Cairncross JG; Department of Clinical Neurosciences, University of Calgary, Calgary, T2N 2T9 AB, Canada; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, T2N 4Z6 AB, Canada., Chan JA; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, T2N 4Z6 AB, Canada; Department of Pathology & Laboratory Medicine, University of Calgary, Calgary, T2L 2K8 AB, Canada., Kelly JJP; Department of Clinical Neurosciences, University of Calgary, Calgary, T2N 2T9 AB, Canada; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, T2N 4Z6 AB, Canada., Marra MA; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, V5Z 4S6 BC, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, V6H 3N1 BC, Canada. Electronic address: mmarra@bcgsc.ca.

Publikováno v: Cancer cell [Cancer Cell] 2022 Apr 11; Vol. 40 (4), pp. 379-392.e9. Date of Electronic Publication: 2022 Mar 17.

Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression.

Autor: De Boeck A; Clark Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Ahn BY; Clark Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., D'Mello C; Clark Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Lun X; Clark Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Menon SV; Clark Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Alshehri MM; Clark Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia., Szulzewsky F; Divison of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, United States., Shen Y; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada., Khan L; Clark Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Dang NH; Clark Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Reichardt E; Clark Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Goring KA; Clark Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., King J; Clark Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Grisdale CJ; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada., Grinshtein N; Department of Molecular Genetics, University of Toronto and Program in Neurosciences and Mental Health, Hospital for Sick Children, Toronto, ON, Canada., Hambardzumyan D; Department of Oncological Sciences, The Tisch Cancer Institute and the Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York, United States., Reilly KM; Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States., Blough MD; Clark Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Cairncross JG; Clark Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Yong VW; Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Marra MA; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada., Jones SJM; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada., Kaplan DR; Department of Molecular Genetics, University of Toronto and Program in Neurosciences and Mental Health, Hospital for Sick Children, Toronto, ON, Canada., McCoy KD; Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Holland EC; Divison of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, United States., Bose P; Clark Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Chan JA; Clark Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Department of Pathology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Robbins SM; Clark Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. srobbins@ucalgary.ca.; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. srobbins@ucalgary.ca., Senger DL; Clark Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. senger@ucalgary.ca.; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. senger@ucalgary.ca.

Publikováno v: Nature communications [Nat Commun] 2020 Oct 05; Vol. 11 (1), pp. 4997. Date of Electronic Publication: 2020 Oct 05.

Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.

Autor: Shen Y; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4S6., Grisdale CJ; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4S6., Islam SA; Center for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, BC, Canada V5Z 4H4.; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada V6H 3N1., Bose P; Department of Biochemistry & Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada T2N 1N4.; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada T2N 4N2.; Department of Surgery, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada T2N 2T9.; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada T2N 4Z6., Lever J; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4S6., Zhao EY; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4S6., Grinshtein N; Program in Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON, Canada M5G 1X8., Ma Y; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4S6., Mungall AJ; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4S6., Moore RA; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4S6., Lun X; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada T2N 4N2.; Clark H. Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada T2N 4Z6., Senger DL; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada T2N 4N2.; Clark H. Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada T2N 4Z6., Robbins SM; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada T2N 4N2.; Clark H. Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada T2N 4Z6., Wang AY; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada T2N 4N1., MacIsaac JL; Center for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, BC, Canada V5Z 4H4., Kobor MS; Center for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, BC, Canada V5Z 4H4.; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada V6H 3N1., Luchman HA; Clark H. Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada T2N 4Z6.; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada T2N 4N1., Weiss S; Clark H. Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada T2N 4Z6.; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada T2N 4N1.; Department of Cell Biology & Anatomy, University of Calgary, Calgary, AB, Canada T2N 4N1.; Department of Physiology & Pharmacology, University of Calgary, Calgary, AB, Canada T2N 4N1., Chan JA; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada T2N 4Z6.; Department of Pathology & Laboratory Medicine, University of Calgary, Calgary, AB, Canada T2L 2K8., Blough MD; Clark H. Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada T2N 4Z6., Kaplan DR; Program in Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON, Canada M5G 1X8.; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada M5S 1A8., Cairncross JG; Clark H. Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada T2N 4Z6.; Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada T2N 2T9., Marra MA; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4S6.; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada V6H 3N1., Jones SJM; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4S6; sjones@bcgsc.ca.; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada V6H 3N1.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2019 Sep 17; Vol. 116 (38), pp. 19098-19108. Date of Electronic Publication: 2019 Aug 30.